B440 / Immunorock - LARVOL DELTA

Phase 1 study of B440, an oral Bifidobacterium-engineered WT1 cancer vaccine, in patients with metastatic urothelial cancer. (ASCO 2025) - P1 | "B440 exhibited a favorable safety profile and no DLTs up to 1,600 mg. The induction of WT1-specific immunity correlated with improved PFS during B440 therapy and enhanced responses upon pembrolizumab rechallenge. These data support further investigation of B440 in larger, randomized trials and potential combination with other immunotherapies in WT1-expressing malignancies."

Clinical • Metastases • P1 data • Bladder Cancer • Genito-urinary Cancer • Head and Neck Cancer • Kidney Cancer • Oncology • Oral Cancer • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer • Wilms Tumor • IFNG • IL6 • WT1